NCT06258525
SAMe in Prevention of Oxaliplatin-associated Liver Injury
StatusNot Yet Recruiting
PhasePhase 2
SponsorCedars-Sinai Medical Center
Primary completion (estimated)
At risk: Primary completion moved at least 1 year 4 months later across 2 updates.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 2028 to Jan 2030
- Start date pushed from Oct 2026 to Jan 2027
Notable Start date: Jul 2026 to Oct 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 38 words
- Primary and study completion pushed from Aug 2028 to Oct 2028
- Secondary endpoints: details revised at 3 of 6 entries
- Site contacts updated at 2 of 2 sites
- Notable Start date: Mar 2026 to Jul 2026
- Primary and study completion pushed from Jun 2028 to Aug 2028
- Site contacts updated at 2 of 2 sites
- Notable Start date: Dec 2025 to Mar 2026
- Primary and study completion dates: Apr 2028 to Jun 2028
- Notable Start date: Sep 15, 2025 to Dec 2025
- Primary and study completion dates: Feb 15, 2028 to Apr 2028
Show 5 earlier versionsHide 5 earlier versions
- Notable Start date: Jul 15, 2025 to Sep 15, 2025
- Primary and study completion dates: Dec 15, 2027 to Feb 15, 2028
- Notable Start date: Apr 15, 2025 to Jul 15, 2025
- Primary and study completion dates: Nov 15, 2027 to Dec 15, 2027
- Notable Primary and study completion dates: Oct 15, 2026 to Nov 15, 2027
- Start date: Aug 1, 2024 to Apr 15, 2025
- Site contacts updated at 2 of 2 sites
- Notable Start date: Apr 15, 2024 to Aug 1, 2024v3
- Notable Primary endpoint revisedv2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
To evaluate the efficacy of SAMe in preventing oxaliplatin associated liver injury as determined by lack of injury on histopathologic analysis in patients with liver only stage IV colorectal cancer.
Timeframe: 8 months
Secondary (6)
To Estimate the Objective Response Rate (ORR) of SAMe when taken with oxaliplatin based chemotherapy.
To evaluate changes in average estimated blood loss (EBL) in patients undergoing liver resection as compared to historical controls.
To evaluate length of hospital stay (LOS) in patients undergoing liver resection as compared to historical controls.
To examine if SAMe can decrease treatment-delays in oxaliplatin-based chemotherapy.
To examine if SAMe can decrease dose-reductions in oxaliplatin-based chemotherapy.
Show 1 moreShow less
To evaluate safety and tolerability of SAMe in combination with SOC oxaliplatin based systemic therapy.
Arms and interventions
Single ArmExperimental
Radiation: Standard of care oxaliplatin-based chemotherapy
Dietary supplements: S-adenosylmethionine (SAMe) supplement
Procedures: Surgery
Sites
2 sites in 1 country